124 related articles for article (PubMed ID: 26905040)
21. Stable Evans Blue Derived Exendin-4 Peptide for Type 2 Diabetes Treatment.
Liu Y; Wang G; Zhang H; Ma Y; Lang L; Jacobson O; Kiesewetter DO; Zhu L; Gao S; Ma Q; Chen X
Bioconjug Chem; 2016 Jan; 27(1):54-8. PubMed ID: 26641886
[TBL] [Abstract][Full Text] [Related]
22. Inhibitory effect of exendin-4 on secretory group IIA phospholipase A2.
Lee W; Kwak S; Lee HS; Na DH; Lee YM; Bae JS
Biochem Biophys Res Commun; 2015 Apr; 459(4):650-4. PubMed ID: 25757907
[TBL] [Abstract][Full Text] [Related]
23. A site-specific PEGylated analog of exendin-4 with improved pharmacokinetics and pharmacodynamics in vivo.
Gao M; Jin Y; Tong Y; Tian H; Gao X; Yao W
J Pharm Pharmacol; 2012 Nov; 64(11):1646-53. PubMed ID: 23058052
[TBL] [Abstract][Full Text] [Related]
24. Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes.
Kim H; Park H; Lee J; Kim TH; Lee ES; Oh KT; Lee KC; Youn YS
Biomaterials; 2011 Feb; 32(6):1685-93. PubMed ID: 21126761
[TBL] [Abstract][Full Text] [Related]
25. Pulmonary administered palmitic-acid modified exendin-4 peptide prolongs hypoglycemia in type 2 diabetic db/db mice.
Lee J; Lee C; Kim TH; Chi SC; Moon HR; Oh KT; Lee ES; Lee KC; Youn YS
Regul Pept; 2012 Aug; 177(1-3):68-72. PubMed ID: 22561689
[TBL] [Abstract][Full Text] [Related]
26. The role of clusterin on pancreatic beta cell regeneration after exendin-4 treatment in neonatal streptozotocin administrated rats.
Kaya-Dagistanli F; Ozturk M
Acta Histochem; 2013 Jul; 115(6):577-86. PubMed ID: 23351716
[TBL] [Abstract][Full Text] [Related]
27. Dual Functioned Pegylated Phospholipid Micelles Containing Cationic Antimicrobial Decapeptide for Treating Sepsis.
Lee W; Park EJ; Min G; Choi J; Na DH; Bae JS
Theranostics; 2017; 7(15):3759-3767. PubMed ID: 29109774
[TBL] [Abstract][Full Text] [Related]
28. Exendin-4, a GLP-1 receptor agonist, stimulates pituitary-adrenocortical axis in the rat: Investigations into the mechanism(s) underlying Ex4 effect.
Malendowicz LK; Nussdorfer GG; Nowak KW; Ziolkowska A; Tortorella C; Trejter M
Int J Mol Med; 2003 Aug; 12(2):237-41. PubMed ID: 12851724
[TBL] [Abstract][Full Text] [Related]
29. PEGylated lysozymes with anti-septic effects in human endothelial cells and in mice.
Lee W; Park EJ; Kwak S; Kim Y; Na DH; Bae JS
Biochem Biophys Res Commun; 2015 Apr; 459(4):662-7. PubMed ID: 25769950
[TBL] [Abstract][Full Text] [Related]
30. Immunity against a therapeutic xenoprotein/Fc construct delivered by gene transfer is reduced through binding to the inhibitory receptor FcγRIIb.
Liang Y; Qiu H; Glinka Y; Lazarus AH; Ni H; Prud'homme GJ; Wang Q
J Gene Med; 2011 Sep; 13(9):470-7. PubMed ID: 21786368
[TBL] [Abstract][Full Text] [Related]
31. Role of phosphatidylinositol 3-kinasegamma in the beta-cell: interactions with glucagon-like peptide-1.
Li LX; MacDonald PE; Ahn DS; Oudit GY; Backx PH; Brubaker PL
Endocrinology; 2006 Jul; 147(7):3318-25. PubMed ID: 16574789
[TBL] [Abstract][Full Text] [Related]
32. Rational design of α-helix-stabilized exendin-4 analogues.
Rovó P; Farkas V; Stráner P; Szabó M; Jermendy A; Hegyi O; Tóth GK; Perczel A
Biochemistry; 2014 Jun; 53(22):3540-52. PubMed ID: 24828921
[TBL] [Abstract][Full Text] [Related]
33. Recombination and functional studies of a dual-action peptide for diabetes.
Zheng J; Zhu Y; Yan Q; Zhong M; Zhao S; Liu Y
J Drug Target; 2013 May; 21(5):443-9. PubMed ID: 23336209
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of PEGylated exendin-4 released from poly (lactic-co-glycolic acid) microspheres for antidiabetic therapy.
Lim SM; Eom HN; Jiang HH; Sohn M; Lee KC
J Pharm Sci; 2015 Jan; 104(1):72-80. PubMed ID: 25407390
[TBL] [Abstract][Full Text] [Related]
35. Self-assembled glycol chitosan nanogels containing palmityl-acylated exendin-4 peptide as a long-acting anti-diabetic inhalation system.
Lee J; Lee C; Kim TH; Lee ES; Shin BS; Chi SC; Park ES; Lee KC; Youn YS
J Control Release; 2012 Aug; 161(3):728-34. PubMed ID: 22634071
[TBL] [Abstract][Full Text] [Related]
36. The role of exendin-4-conjugated superparamagnetic iron oxide nanoparticles in beta-cell-targeted MRI.
Zhang B; Yang B; Zhai C; Jiang B; Wu Y
Biomaterials; 2013 Jul; 34(23):5843-52. PubMed ID: 23642536
[TBL] [Abstract][Full Text] [Related]
37. The Food Environment, Preference, and Experience Modulate the Effects of Exendin-4 on Food Intake and Reward.
Mella R; Schmidt CB; Romagnoli PP; Teske JA; Perez-Leighton C
Obesity (Silver Spring); 2017 Nov; 25(11):1844-1851. PubMed ID: 29086500
[TBL] [Abstract][Full Text] [Related]
38. Facile construction of sulfanyl-terminated poly(ethylene glycol)-brushed layer on a gold surface for protein immobilization by the combined use of sulfanyl-ended telechelic and semitelechelic poly(ethylene glycol)s.
Yoshimoto K; Hirase T; Nemoto S; Hatta T; Nagasaki Y
Langmuir; 2008 Sep; 24(17):9623-9. PubMed ID: 18666758
[TBL] [Abstract][Full Text] [Related]
39. A second-generation glucagon-like peptide-1 receptor agonist mitigates vomiting and anorexia while retaining glucoregulatory potency in lean diabetic and emetic mammalian models.
Borner T; Shaulson ED; Tinsley IC; Stein LM; Horn CC; Hayes MR; Doyle RP; De Jonghe BC
Diabetes Obes Metab; 2020 Oct; 22(10):1729-1741. PubMed ID: 32410372
[TBL] [Abstract][Full Text] [Related]
40. Glucagon-like peptide-1 agonist exendin-4 leads to reduction of weight and caloric intake in a rat model of hypothalamic obesity.
Elfers CT; Simmons JH; Roth CL
Horm Res Paediatr; 2012; 78(1):47-53. PubMed ID: 22831885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
